<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The efficacy and safety of a new platelet-activating factor receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, E5880, were investigated for preventing <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> after <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> (SAH) in 71 patients with SAH who underwent surgery for ruptured <z:hpo ids='HP_0002617'>aneurysms</z:hpo> within 3 days </plain></SENT>
<SENT sid="1" pm="."><plain>Intravenous E5880 administration (300 micrograms or 1200 micrograms twice daily) was begun within 4 days and continued for 14 days </plain></SENT>
<SENT sid="2" pm="."><plain>The incidence of symptomatic vasospasm, low-density area on computed tomography, and angiographic vasospasm was lower than in placebo groups in previous studies </plain></SENT>
<SENT sid="3" pm="."><plain>Clinical outcome was favorable compared with previous studies </plain></SENT>
<SENT sid="4" pm="."><plain>No clinically important adverse events were observed </plain></SENT>
<SENT sid="5" pm="."><plain>These results suggest that E5880 is safe and effective in the treatment of patients with <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> due to SAH </plain></SENT>
</text></document>